A vaccine for lung cancer using exosomes from stem cells
Official title: A lung cancer vaccine based on exosomes of induced pluripotent stem cells
Funded at University of Louisville · NIH-10651014 · Data updated 2026-11-12
This study is testing a new lung cancer vaccine made from tiny particles that could help your immune system recognize and fight lung tumors while being safe for healthy cells, and it’s looking for patients to join the trials.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $402,401 |
| NIH project number | 1R21CA280453-01 |
| Project ID | NIH-10651014 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults at risk for or diagnosed with lung cancer.
✕Less likely to help
Patients with lung cancer who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research investigates a novel lung cancer vaccine that utilizes exosomes derived from induced pluripotent stem cells (iPSCs). The approach aims to target multiple tumor-associated antigens that are present in lung tumors but absent in normal tissues, potentially enhancing the vaccine's effectiveness. By leveraging the similarities between iPSCs and tumor cells, the study will explore how these exosomes can stimulate the immune system to attack lung tumor-initiating cells. Patients may be involved in trials to assess the safety and efficacy of this innovative vaccine.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine for preventing lung cancer.
How similar studies have gone: While there have been attempts to develop lung cancer vaccines, this approach using iPSC-derived exosomes is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Li, Chi — University of Louisville
- Study coordinator: Li, Chi
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.